Feng Wang1, Yanyan Wang1, Yan Zhu2, Xiaosong Liu3, Hui Xia1, Xian Yang1, Guiju Sun4. 1. Key Laboratory of Environmental Medicine and Engineering of Ministry of Education, Department of Nutrition and Food Hygiene, School of Public Health, Southeast University, Nanjing, China. 2. Food Nutrition and Safety Society in Yixing, Yixing, China. 3. Guanlin Hospital in Yixing, Yixing, China. 4. Key Laboratory of Environmental Medicine and Engineering of Ministry of Education, Department of Nutrition and Food Hygiene, School of Public Health, Southeast University, Nanjing, China. gjsun@seu.edu.cn.
Abstract
PURPOSE: This study aimed to determine the effects of fish oil-derived n-3 PUFA on glycemic control and lipid profiles in type 2 diabetic patients with abdominal obesity. METHODS: In a randomized, double-blind, placebo-controlled trial, 100 type 2 diabetic patients with abdominal obesity were randomized into two groups including 4 g/day of fish oil (2.4 g n-3 PUFA) or placebo (corn oil) for 6 months. Serum fatty acid, body composition, as well as markers of glucose regulation and lipid parameters were measured before and after intervention. RESULTS:Thirty-five men and 64 women aged 65.4 ± 5.3 years completed the intervention. Although body composition was unchanged, serum EPA and DHA were higher in the fish oil group than those in the placebo group (P < 0.001 and P < 0.001, respectively). Serum triglyceride (TG) decreased (P = 0.007), whereas high-density lipoprotein cholesterol (HDL-C) increased (P = 0.006) in the fish oil group compared with the placebo group after 6 months. Serum total cholesterol, low-density lipoprotein cholesterol (LDL-C), the ratio of LDL-C to HDL-C, and glycemic control (measured by serum glucose, glycated hemoglobin, insulin, and homeostasis model assessment-insulin resistance) were not significantly different between the two groups after 6 months. CONCLUSIONS: This study showed that 6 months of fish oil supplement had no statistically significant effects on glycemic control, but improved TG and HDL-C in type 2 diabetic patients with abdominal obesity. TRIAL REGISTRATION: Chictr.org ChiCTR-TRC-14005084.
RCT Entities:
PURPOSE: This study aimed to determine the effects of fish oil-derived n-3 PUFA on glycemic control and lipid profiles in type 2 diabeticpatients with abdominal obesity. METHODS: In a randomized, double-blind, placebo-controlled trial, 100 type 2 diabeticpatients with abdominal obesity were randomized into two groups including 4 g/day of fish oil (2.4 g n-3 PUFA) or placebo (corn oil) for 6 months. Serum fatty acid, body composition, as well as markers of glucose regulation and lipid parameters were measured before and after intervention. RESULTS: Thirty-five men and 64 women aged 65.4 ± 5.3 years completed the intervention. Although body composition was unchanged, serum EPA and DHA were higher in the fish oil group than those in the placebo group (P < 0.001 and P < 0.001, respectively). Serum triglyceride (TG) decreased (P = 0.007), whereas high-density lipoprotein cholesterol (HDL-C) increased (P = 0.006) in the fish oil group compared with the placebo group after 6 months. Serum total cholesterol, low-density lipoprotein cholesterol (LDL-C), the ratio of LDL-C to HDL-C, and glycemic control (measured by serum glucose, glycated hemoglobin, insulin, and homeostasis model assessment-insulin resistance) were not significantly different between the two groups after 6 months. CONCLUSIONS: This study showed that 6 months of fish oil supplement had no statistically significant effects on glycemic control, but improved TG and HDL-C in type 2 diabeticpatients with abdominal obesity. TRIAL REGISTRATION: Chictr.org ChiCTR-TRC-14005084.
Entities:
Keywords:
Abdominal obesity; Fish oil; Glycemic control; Lipid levels; Type 2 diabetes; n-3 polyunsaturated fatty acids
Authors: Louise F Clark; M C Thivierge; Claire A Kidd; Susan C McGeoch; Prakash Abraham; Donald W M Pearson; Graham W Horgan; Grietje Holtrop; Frank Thies; Gerald E Lobley Journal: Br J Nutr Date: 2015-11-05 Impact factor: 3.718
Authors: Manas Kaushik; Dariush Mozaffarian; Donna Spiegelman; JoAnn E Manson; Walter C Willett; Frank B Hu Journal: Am J Clin Nutr Date: 2009-07-22 Impact factor: 7.045
Authors: Geertruida J van Woudenbergh; Adriana J van Ballegooijen; Anneleen Kuijsten; Eric J G Sijbrands; Frank J A van Rooij; Johanna M Geleijnse; Albert Hofman; Jacqueline C M Witteman; Edith J M Feskens Journal: Diabetes Care Date: 2009-08-12 Impact factor: 19.112
Authors: Roel J T Mocking; Johanna Assies; Mariska Bot; Eugene H J M Jansen; Aart H Schene; François Pouwer Journal: PLoS One Date: 2012-11-28 Impact factor: 3.240
Authors: Alex Pizzini; Lukas Lunger; Egon Demetz; Richard Hilbe; Guenter Weiss; Christoph Ebenbichler; Ivan Tancevski Journal: Nutrients Date: 2017-10-06 Impact factor: 5.717